Allezoe Medical Holdings, Inc.
OTC Bulletin Board : ALZM

June 28, 2011 09:01 ET

Allezoe (ALZM) Board of Directors Nominates New Chairman

Chairman Michael Gelmon Will Spearhead Acquisition Period

FRISCO, TEXAS--(Marketwire - June 28, 2011) - Allezoe Medical Holdings, Inc. (OTCBB:ALZM) today announces that, after a unanimous vote by the Board of Directors of the Company, Michael Gelmon, LL.B has been appointed the Chairman of Allezoe.

Allezoe's newly expanded Board of Directors met for the first time on June 24, 2011. On May 31 of this year, Michael Choo, Caroline Pinell, and Michael Gelmon joined already-seated members Michael Holder and Hyman White on the Allezoe Board, bringing the number of Directors to five.

Mr. Gelmon has extensive experience with several public companies in the capacity of both CEO and Director. Most notably, he was the founding shareholder, Director, and Head of Acquisitions and Real Estate for Domino's Pizza of Canada, Ltd. In addition to his business expertise, Gelmon has a law degree from King's College at University of London.

Currently, Allezoe's sole subsidiary is Organ Transport Systems ("OTS"), which plans to redefine human organ transplantation through better preservation with its LifeCradle® product line. Organ Transport Systems intends to offer this device as a potential bridge for the large gap between available donor organs and actual transplantations. OTS is preparing for clinical trials and commercialization of its technology, and recently attended the International Society for Heart and Lung Transplantation ( conference, where its technology was well-received by peers.

In his tenure as Chairman of the Board, Gelmon intends to oversee Allezoe's growth via strategic acquisitions in the medical device sector and related arenas. Gelmon says, "Organ Transport Systems sets the standard of high-quality medical technology we seek to bring under the Allezoe umbrella. We are interested in those technologies that address widespread medical issues or long-standing holes in healthcare services. We are specifically seeking out companies creating the biggest change, by addressing urgent health issues affecting large groups of people."

Allezoe CEO and Director Michael Holder says, "Michael Gelmon's expertise in overseeing successful corporate expansions through acquisitions and successful fundraising, combined with his enthusiasm for Allezoe's long-term potential, will make him an excellent Chairman for our Board."


This announcement is not an offer to sell any Allezoe ("ALZM") related securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of ALZM may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and includes, without limitation, statements regarding ALZM's plan of business operations, product research and development activities, anticipated revenues and expenses and potential contractual arrangements and obligations. Also, our management may make forward-looking statements orally to investors, analysts, the media and others. Any statements made in this news release about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. These risks and others are included from time to time in documents we file with the Securities and Exchange Commission, including but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. Other unknown or unpredictable factors also could have material adverse effects on our future results. Accordingly, you should not place undue reliance on these forward-looking statements. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The Company takes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the Company. The Company's SEC filings are available at

Contact Information